072020.Kq
072020.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and medical research services.
Business. 072020.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and medical research services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
072020.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and medical research services.
The company maintains a strong liquidity position, with a current ratio of 4.27, indicating that it has more than four times the current assets to cover its current liabilities. Its cash and equivalents amount to 10,468,099,780 KRW, and it has a free cash flow of 4,878,596,560 KRW, which supports its operational flexibility and capacity for reinvestment. The debt-to-equity ratio is 0.07, suggesting a conservative capital structure with minimal reliance on debt financing.
In terms of profitability, the company reports a return on equity (ROE) of 5.84% and a return on assets (ROA) of 5.01%, both of which are in line with industry norms for pharmaceutical firms. These metrics indicate that the company is effectively utilizing its equity and asset base to generate returns. The operating margin, calculated as operating income divided by revenue, is 13.2%, which is a strong indicator of cost control and pricing power in the industry.
The company's revenue is concentrated in its core pharmaceutical operations, with no disclosed geographic diversification in the provided data. This suggests that the company's performance is closely tied to the markets in which it operates, and any regional economic or regulatory shifts could have a direct impact on its financial results.
Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The analyst estimate for EBIT is 11,000,000,000 KRW, which implies a continuation of current performance levels. Historical revenue data shows a consistent trend, with no sharp fluctuations that would suggest volatility in the business model.
The risk assessment indicates a low probability of liquidity and dilution issues, with no immediate filing-based flags detected. The company's low debt levels and strong cash reserves reduce the likelihood of financial distress. Additionally, the absence of dilution risk suggests that the company is not planning to issue new shares in the near term, preserving shareholder value.
Recent events, as reflected in the latest financial filings, show a stable financial position with no material changes in the company's operations or strategic direction. The company has not disclosed any significant new projects or acquisitions that would alter its current trajectory.
- The company has a strong liquidity position with a current ratio of 4.27 and a free cash flow of 4,878,596,560 KRW.
- It maintains a conservative capital structure with a debt-to-equity ratio of 0.07.
- The company's profitability is reflected in a ROE of 5.84% and a ROA of 5.01%.
- Revenue is concentrated in its core pharmaceutical operations, with no disclosed geographic diversification.
- Analyst estimates suggest a stable EBIT of 11,000,000,000 KRW for the next fiscal year.
- The risk assessment indicates a low probability of liquidity and dilution issues.
- **margin_outlook_rationale**: The company's operating margin is expected to remain stable due to consistent cost control and pricing power in the pharmaceutical industry.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 072020.KQ Market data — financials · 2026-05-26
- Choong Ang Vaccine Laboratory Co Ltd Market data — analyst estimates · 2026-05-26